Justin Averback
Associate Partner
专长:
Justin Averback is an Associate Partner at EVERSANA MANAGEMENT CONSULTING, with experience across the development lifecycle, including product commercialization, market research, project management, and brand strategy.
With EVERSANA MANAGEMENT CONSULTING, Justin has collaborated with biopharma and medical device companies of all sizes. He possesses industry experience across therapeutic areas, with expertise in rare diseases and oncology.
Prior to joining EVERSANA MANAGEMENT CONSULTING, Justin was a Consultant in the Life Sciences Advisory division of Navigant Consulting. With this team, he gained experience in corporate strategy, market assessment, valuations, forecasting, data analysis, and brand planning for midsize and top 25 pharmaceutical companies. He has also worked as a Technical Operations Consultant at Alcresta Therapeutics in Newton, MA, where he provided support in the areas of process development, manufacturing, and scaling. In addition, Justin assisted Tissue Analytics Inc. in designing and executing clinical trials for the company’s wound imaging platform.
While at the University of Pennsylvania’s School of Engineering and Applied Sciences working toward his bachelor of science and engineering in biomedical engineering, Justin co-created a balance training device designed for children with cerebral palsy.
Articles by Justin Averback
Harnessing the Commercial Promise of Prescription Drug Use-Related Software (PDURS)
The FDA’s draft guidance on Prescription Drug Use-Related Software (PDURS) offers pharmaceutical manufacturers a novel strategy to enhance a drug’s label by enabling an HCP to prescribe software alongside the drug at the HCP’s discretion. The new framework makes it easier than before to pair software with a medication to help patients manage complex dosing, […]
Point of Attack: Developing a Targeted Oncology Account Engagement Strategy and Tactical Platform
Key account management (KAM) is a more innovative approach to pharmaceutical sales and account engagement. KAM promises to deliver long-term, mutually beneficial partnerships between biopharmaceutical manufacturers and healthcare systems and provider practices (aka target accounts). Pharmaceutical manufacturers in oncology are increasingly moving to a more integrated field model, with a focus on KAM as the […]